This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

New Alzheimer's targets via proteomics

February 12th, 2015

Allan Levey, MD, PhD, chair of neurology at Emory University School of Medicine and director of the Emory Alzheimer's Disease Research Center, is scheduled to give a talk titled "Proteomics Discovery of New Alzheimer's Disease Targets," as part of the Dementia: Research Milestones and Policy Priorities session on Friday, Feb. 13.

The session takes place from 1:00 PM to 2:30 PM, Room LL21D (San Jose Convention Center).

Levey is expected to describe a "beyond the usual suspects" approach to probing for proteins involved in Alzheimer's disease pathology. "Usual suspects" refers to beta-amyloid and tau, two proteins that accumulate in the brains of Alzheimer's patients. Some experimental approaches to Alzheimer's treatment aim at curbing beta amyloid, but have not proven effective.

Taking this approach, Levey and his team have already identified a previously unrecognized type of pathology in the brains of Alzheimer's patients, seen at early stages of the disease. They found tangle-like structures that sequester proteins critical for RNA splicing, a discovery that may have implications for the disease mechanism.

More information:
www.pnas.org/content/110/41/16562.full

Provided by Emory University

Citation: New Alzheimer's targets via proteomics (2015, February 12) retrieved 9 October 2025 from https://sciencex.com/wire-news/185216701/new-alzheimers-targets-via-proteomics.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.